Have a read.
From an old article.
IMU’s front runner drug candidate HER-Vaxx, is already in Phase 1b and Phase 2 trials and is interestingly further advanced than Regeneron’s cancer therapies before Regeneron was acquired for $1.6 billion by Roche.
IMU is looking to attract big pharma’s attention by 2020.
HER-Vaxx targets the same receptor as the two leading antibody drugs on the market, Herceptin and Perjeta, with annual sales of US$8.2 billion in a market predicted to generate sales of US$36 billion by 2025.
IMU is looking to commercialise a treatment that has improved efficacy over existing treatments and is more cost efficient, which would give it a strong position in this market.
https://www.nextbiotech.com.au/company/imu/
Cheers
- Forums
- ASX - By Stock
- IMU
- Imugene - Charts & Price Action (New thread)
Imugene - Charts & Price Action (New thread), page-238
-
-
- There are more pages in this discussion • 1,561 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.9¢ |
Change
0.001(1.04%) |
Mkt cap ! $356.9M |
Open | High | Low | Value | Volume |
4.9¢ | 4.9¢ | 4.8¢ | $119.6K | 2.461M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
69 | 7885649 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 2719025 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
67 | 7871773 | 0.048 |
47 | 4490892 | 0.047 |
60 | 3870226 | 0.046 |
62 | 7391520 | 0.045 |
13 | 2059852 | 0.044 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 2723249 | 23 |
0.050 | 4580270 | 22 |
0.051 | 7060073 | 18 |
0.052 | 2488295 | 11 |
0.053 | 1158504 | 8 |
Last trade - 11.47am 04/10/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |